Actively Recruiting
Famotidine and Antacids for Treatment of Dyspepsia
Led by Stony Brook University · Updated on 2025-05-01
80
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.
CONDITIONS
Official Title
Famotidine and Antacids for Treatment of Dyspepsia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Diagnosed with dyspepsia
- Presenting to the emergency department with upper abdominal pain score of at least 3
You will not qualify if you...
- Allergy to any ingredient in Maalox, Mylanta, or Famotidine
- Moderate to severe kidney problems
- Kidney failure
- Pregnant or nursing
- Verbal pain score less than 3
- Unable to take oral medications
- Bowel obstruction
- Taken proton pump inhibitors within 2 hours before study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stony Brook University Hospital
Stony Brook, New York, United States, 11794
Actively Recruiting
Research Team
A
Adam Singer, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here